Investments and investor services
IPO Roundup: Peloton Therapeutics, Rattler Midstream headline the week's slate of public offerings
Three biopharmaceutical companies are going public with one Texas oil company thrown in the mix
Company
NYSE:NVS
Novartis provides healthcare solutions that address the evolving needs of patients and societies.
44 stories · page 2 of 3
Investments and investor services
Three biopharmaceutical companies are going public with one Texas oil company thrown in the mix
Investments and investor services
Also making moves on Tuesday were Novartis, United States Steel, Zogenix and Kodak
Missouri is expected to generate between $175 million to $275 million in annual marijuana sales, as per Marijuana Business Daily data
Results from the Phase 2b clinical trial of liver disease drug Emriscan failed to show a meaningful difference when compared with the placebo
Investments and investor services
The global cannabis market opportunity could top $200 billion over the long term and the companies Benchmark is recommending are ideally positioned to take advantage
Hardware & electrical equipment
CEO Brendan Kennedy tells CNBC's Jim Cramer that the cannabis space is potentially worth US$150bn
The Canadian cannabis group has received the required permits from Germany and Canada to sell whole flower cannabis products in Germany
The downgrade came as Tilray secured another supply agreement, ahead of Canada’s legalization of recreational cannabis next month
The research note puts the value per share at 14 cents each, or 12 cents after dilutions.
Oppenheimer says company's cash position 'should continue to provide operational freedom'
Archive
Proactive picks out some highlight stocks from Wednesday's pre-market trade
The struggling microcap has signed a discovery and development deal with a giant of the pharmaceutical industry
There were some big names taking a hit on Wednesday shedding light on the state of the global economy and none bigger than Apple...
Below are some of the main news-driven share price changes as at 2:40 p.m. in New York.
GenVec says Novartis will continue to collect safety data on the nine patients currently enrolled in the study before determining whether to proceed with incremental patients.
Wall Street lost more than 1 percent before the close today as market turmoil in China overshadowed Greece's debt crisis, while trading on the New York Stock Exchange resumed after a three-hour halt. The S&P 500 (INDEXSP:.INX) sank 1.5
The new drug is likely to be very popular in the market and a consensus of Thomson-Reuters sector analysts expect annual sales of US$4.4 billion by 2020
Wall Street stretched its losses in heavy trading today after a collapse in Greek bailout talks raised fears that the country could be the first to exit the euro zone. The S&P 500 (INDEXSP:.INX) skidded 2 percent to 2,058.63 at 3:45 p.m